- $1.79bn
- $1.87bn
- $109.79m
Brief: Urogen Pharma Announced Final Results From Single-Arm, Open-Label OPTIMA II Phase 2B Trial Evaluating Efficacy And Safety Of Investigational UGNn--102
Brief: Urogen Pharma Says CMS Issues Permanent J-Code For Urogen's Jelmyto
Brief: Urogen Pharma Expands Executive Team To Accelerate Platform Innovation And Drive Commercial Growth
Urogen Pharma: Drops to 4-month low after mid-stage trial disappoints
Brief: Urogen Pharma Announces Update On The Phase 2 Trial Of An RTgel Hydrogel Formulation In Combination With Botox
Brief: UroGen Pharma Q2 Loss Per Share $1.44
Brief: Urogen Announces Positive Data From Pivotal Olympus Trial Evaluating Jelmyto In Patients With Low-Grade Upper Tract Urothelial Cancer
Brief: Urogen Pharma Reports Q1 2020 Financial Results
UroGen Pharma: Jumps after cancer drug gets FDA nod
Brief: FDA Approves Urogen Pharma's Jelmyto To Treat Adults With Low-Grade Upper Tract Urothelial Cancer
UroGen: Rises as cancer drug shows promise in interim data
Brief: UroGen Announces Positive Interim Data From Phase 2B Study Of UGN-102 In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
Clinical trials, drug launches, approvals likely to be hit by coronavirus - William Blair
Brief: Urogen Pharma Reports Q4 Loss Per Share Of $1.86
Brief: Urogen Pharma Posts Q4 Loss Per Share Of $1.86
Brief: Urogen Pharma Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing
Urogen Pharma: Submits FDA application for bladder cancer gel, shares jump
Brief: Urogen Pharma Q3 Loss Per Share $1.06
Brief: UroGen Pharma Announces Exclusive License Agreement With Agenus Inc To Advance Treatment Of Urinary Tract Cancers